Moderna (MRNA) And Merck (MRK) Melanoma Vaccine Trial Success Sparks Massive Stock Surge And Investor Caution
Moderna’s personalized mRNA cancer vaccine has shown success in a late-stage clinical trial, potentially transforming how doctors treat the deadliest form of skin cancer. The vaccine, developed in combination with Merck’s immunotherapy Keytruda, met its primary goals in the Phase 3 INTerpath-001 study involving more than 1,100 patients with higher-risk or advanced melanoma. Patients enrolled…